Our study evaluated a panel of breast cancer cell lines belonging to the estrogen receptor positive (ER+) or triple negative (TN) subtypes, with a particular focus on mitochondrial metabolism and ROS management systems to suggest specific metabolic vulnerabilities that could define them or be used as targets for therapy. Here, ESR1 is linked to breast cancer.